Drugs / Levcromakalim
last change Jul 2025 re-read 2 minutes ago

Levcromakalim

also known as BRL-38227

Small molecule

Investigated by
Danish Headache Center · Novartis

Trials 2 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT05889442 Mar → Jun 2023 migraine without aura Danish Headache Center Completed No outcome recorded
NCT05243953 Mar → Jul 2022 Danish Headache Center Completed No outcome recorded
Also used as a comparator or background therapy in 10 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase not applicable10 trials
NCT05565001 Comparator Sep 2022 → Jul 2023 migraine with aura, migraine without aura Danish Headache Center Unknown No outcome recorded
NCT05211050 Comparator Mar 2022 → Nov 2023 migraine without aura Danish Headache Center Completed No outcome recorded
NCT04905654 Comparator Sep 2021 → May 2023 migraine disorder Danish Headache Center Completed No outcome recorded
NCT05093582 Comparator Jun 2021 → Sep 2022 cluster headache syndrome Danish Headache Center Completed No outcome recorded
NCT04853797 Comparator May 2021 → Jul 2025 migraine without aura Danish Headache Center Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as Levcromakalim ClinicalTrials.gov intervention name — accepted as the source's own label NCT05889442
11

NCT03609008

NCT04853797

NCT03228355

NCT05565001

NCT03886922

NCT05211050

NCT05243953

NCT03726242

NCT05093582

NCT04905654

NCT04012047

Known as BRL-38227 ChEMBL registry synonym — accepted as the source's own label CHEMBL100
Action Activate “ATP-sensitive potassium (KATP ) channel opener levcromakalim induces migraine attacks in migraine patients.” PMID 31535367 Sep 2019
Modality Small molecule CHEMBL100
Route Intravenous Intravenous administration of levcromakalim or placebo for 20 minutes.” NCT03609008